Compare Amplitude Inc (AMPL) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs BridgeBio Pharma Inc — how do they compare? Amplitude Inc trades at $12.78 (market cap $1.52B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 10.9× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| AMPL | BBIO | |
|---|---|---|
Market Cap | $1.52B | $16.61B |
Sector | Technology | Health |
52-Week High | $12.30 | $90.17 |
52-Week Low | $5.61 | $47.29 |
Enterprise Value | $1.39B | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amplitude (AMPL) trades at $11.26, up 4.55% in 24 hours, with a bullish technical signal and strong analyst support. Revenue growth is robust, reaching $343.21 million in 2025, but profitability remains a challenge with a net loss of $88.54 million. Recent news highlights investor conference participation and Q2 2026 results that met revenue estimates but missed on EPS.
The outlook is mixed: strong revenue growth and a $12.08 consensus price target suggest upside, but persistent losses, negative cash flow, and ongoing legal investigations pose significant risks. Investors should weigh growth potential against fundamental weaknesses and sentiment shifts from recent insider sales and legal scrutiny.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
